Cervical Cancer Screening

  • Print
  • Email

The harm and pathogeny of cervial cancer

HPV has been identified as the leading cause of cervical cancer in women, as well as a growing risk factor in orpharyngeal cancer. 99.7% cervical cancer can be found in the high-risk type HPV infection. Cervical cancer is one of the most common malignancy among women. Its incidence occupies the second place of women malignant tumor.There are about 500 thousands of new cases of HPV in the world each year, of which 200 thousands women died of cervical cancer. But cervical cancer is the only one currently that can be found and prevented in the early phase, can be cured 100%, is expected to wipe out cancer.

 

 

Human papillomavirus genotyping test kit(PCR-RDB)-19 genotype

1. High sensitivity, good specificity
Clinical trial results showed that: the kit sensitivity and specificity are above 95%.
2. Widely cover various genotype
Covering 19 kinds of HPV subtype, accurately detecting 13 kinds of medium, high risk HPV validated by WHO: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 66; 3 kinds of low risk HPV: 6, 11, 43
3. Extraordinary technology
Using rapid lysis method that is simple and fast, and suit for large-scale clinical sample extraction
Using hot-start enzyme, enhancing specificity of PCR amplification
Using PCR buffer that have strong capacity, to maximum the efficiency of PCR amplification
Using DA8000 automatic nucleic acid hybridization instrument that is automatically rapid hybridization
Fast operation and convenient clinical diagnosis
With internal and external control, excluding false negative and positive reaction
4. Wide applicability
Qualitative PCR system are suitable for a variety of qualitative PCR instrument. Hybrid process can be manually, also can be carried out using DA8000 automatically.
DA8000 hybrid fast, high throughput, hybridization process automatically, humanized operation system, temperature and liquid feeding preciously, good sealing, it is prior instrument for the kit hybrid process.

 

Human papillomavirus genotyping test kit(PCR-RDB)-28 genotype

1. High sensitivity, good specificity
Clinical trial results showed that: the kit sensitivity is 98.3%, specificity is 98.91%.
2. Widely cover various genotype
Covering 28 kinds of HPV subtype, accurately detecting 15 kinds of high risk HPV validated :16、18、31、33、35、39、45、51、52、56、58、59、68、73、82; 3 kinds of medium risk: 26、53、66 ; 10 kinds of low risk HPV: 6、11、40、42、43、44、54、61、81、83
3. Extraordinary technology
A tube of reaction can simultaneously detect 28 kinds of HPV subtypes
Using fiber filter centrifugal column, extracting high-purity nucleic acid
Using hot-start enzyme, enhancing specificity of PCR amplification
Using PCR buffer that have strong capacity, to maximum the efficiency of PCR amplification
Using the UDG enzyme system, effectively prevent PCR from pollution
Using DA8000 automatic nucleic acid hybridization instrument that is automatically rapid hybridization
Fast operation and convenient clinical diagnosis
With internal and external control, excluding false negative and positive reaction
4. Wide applicability
Qualitative PCR system are suitable for a variety of qualitative PCR instrument. Hybrid process can be manually, also can be carried out using DA8000 automatically.
DA8000 hybrid fast, high throughput, hybridization process automatically, humanized operation system, temperature and liquid feeding preciously, good sealing, it is prior instrument for the kit hybrid process.
5. Unique integrated solution
According to our fluorescent PCR  / liquid based cytology products, can be freely combined to form integrated detection scheme. 

 

High-risk human papillomavirus nucleic acid test kit(PCR-Fluorescence Probing) - 8 genotype

1. Rapid detection: A detection of 8 high-risk HPV subtypes (16, 18, 34, 33, 45, 52, 56, 58), almost covering high-risk china population of cervical carcinoma.
2. Simple operation: Closed operation, amplified by PCR in a closed reaction system, monitoring the whole process by detecting fluorescence intensity. When the reaction was ended, results will be analyzed.
3. Qualitative results: accurately evaluated the virus load of the samples
4. High sensitivity, good specificity
Clinical trial results showed that: sensitivity and specificity are above 95%.
5. The result is objective and reliable, without human judgment, automatic collection analysis of experimental data by the instrument.

 

Human papillomavirus nucleic acid test kit(PCR - Fluorescence Probing) - 18 genotype

1. High sensitivity, good specificity
Clinical trial results showed that: the kit sensitivity is 98.6%, specificity is 98.4%.
2. Widely cover various genotype
Simultaneously detecting 15 kinds of high-risk HPV subtypes validated by WHO: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82. 3 kinds of medium risk HPV subtypes: 26, 53, 66.
3. Extraordinary technology
Using fiber filter centrifugal column, extracting high-purity nucleic acid
Using Taqman fluorescent probe that is highly sensitive, good specificity;
Using hot-start enzyme, enhancing specificity of PCR amplification
Using PCR buffer that have strong capacity, to maximum the efficiency of PCR amplification
Using closed tube operation , no treatment after operation
With internal and external control, excluding false negative and positive reaction
4. Wide applicability
Suitable for a variety of qualitative PCR instrument, for example BIO-RAD CFX96,ABI7300/7500,Roche Lightcycle 480 etc;
The BIO-RAD CFX96 has a fast operating speed, 5 channel detection, high throughput, convenient use and maintenance, low maintenance costs, and is the prior instrument for the kit.

 

Human papillomavirus nucleic acid test kit(PCR - Fluorescence Probing) - 20 genotype

1.High sensitivity, good specificity
Clinical trial results showed that: the kit sensitivity and specificity are above 98%.
2. Widely cover various genotype
Covering 20 kinds of HPV subtypes, accurately detecting 15 kinds of high risk HPV validated by WHO : 16、18、31、33、35、39、45、51、52、56、58、59、68、73、82;3 kinds of medium risk HPV:26、53、66;2 kinds of low risk HPV: 6、11
3. Extraordinary technology
Using 4 channel detecion, capable of detecting HPV genotyping
Using fiber filter centrifugal column, extracting high-purity nucleic acid
Using Taqman fluorescent probe that is highly sensitive, good specificity;
Using hot-start enzyme, enhancing specificity of PCR amplification
Using closed tube operation , simple and fast, no pollution
With internal and external control, excluding false negative and positive reaction
4. Wide applicability
Suitable for a variety of qualitative PCR instrument, for example BIO-RAD CFX96,ABI7300/7500,Roche Lightcycle 480 etc;
The BIO-RAD CFX96 has a fast operating speed, 5 channel detection, high throughput, convenient use and maintenance, low maintenance costs, and is the prior instrument for the kit.
Cervical cancer is one of the most common gynecologic malignant tumor. In recent years, along with lifestyle changes, the patients who have Cervical cancer become younger, and the number of cases is rising. Study on etiology of cervical cancer have a breakthrough, confirming HPV infection etiology of the exact relationship with cervical cancer, namely high-risk HPV infection is a necessary condition for cervical cancer. 99.7% cervical cancer patients have HPV infections. The company creatively put forward "high-risk HPV DNA check + LBP check" "one-stop" solution. Directly applied real-time quantitative PCR as a high-tech symbol of the molecular biology to livelihood project on the cervical cancer screening, which reflects the latest research results in the field of prevention and treatment of cervical cancer.
1. According to the international agency for research on cancer (IARC) statistics, can be detected in the presence of 99.7% HPV in cervical cancer tissues.
2. HPV infection is the major cause of cervical cancer.
3. 3 best solutions on cervical cancer screening: HPV detection +LBP detection of liquid based cytology.

 Cervical Cancer

 

1. The economical scheme

About 80% HPV detection population are negative. There are no cervical cancer risk for the short term, so screening interval may be extended to 5 years. Thereby the reduced cost without liquid based cytology detection annually is far greater than the cost of the increased cost of HPV detection.
20% population of HPV detection was positive who have risk in cervical cancer. This kind of positive HPV high risk population (especially both cytological detection for ASC-US and LSIT ) screening out from the low risk population in HPV negative, reducing the rate of misdiagnosis.

HPV Detection

2. The best scheme

HPV genotyping detection + liquid based cytology
Clinical value of HPV genotyping
Different high-risk HPV have various carcinogenic risks. HPV16, 18, 33, 58 cancer risk is highest. By detecting HPV genotype to evaluate the risk of patients, making treatment plan.
The same high-risk HPV with persistent infection is highest at oncogenic risk. By genotype detection, the repeated infection was persistent infection of the same genotype or different genotypes, assessing of the risk of treatment.
Before and after treatment, HPV genotype should be detected, judging whether is the thorough treatment or reinfection.

QQ截图20141017144211

 

Related Products

1. Automatic Liquid-based Preparation (LBP) System

2. Sedimentation Liquid Based Cell Production Dyeing System